USANA Health Sciences, Inc. $USNA Stock Sold by Pzena Investment Management LLC

Key Points

• Pzena Investment Management cut its USANA stake by 7.6%, selling 91,604 shares, but still held 1.11 million shares—about 6.03% of the company—at quarter-end.
• USANA’s third-quarter results missed expectations: it reported a loss of $0.11 per share and $205.9 million in revenue, while sales fell 4% year over year.
• The company lowered its FY2026 outlook to net sales approaching $900 million and adjusted EBITDA of about $77 million; analysts also reduced forward earnings estimates, and the stock opened at $13.86.

Pzena Investment Management LLC trimmed its holdings in USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 7.6% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,113,983 shares of the company's stock after selling 91,604 shares during the quarter. Pzena Investment Management LLC owned about 6.03% of USANA Health Sciences worth $16,119,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Versant Capital Management Inc grew its holdings in USANA Health Sciences by 1,472.3% during the 2nd quarter. Versant Capital Management Inc now owns 1,588 shares of the company's stock worth $34,000 after acquiring an additional 1,487 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of USANA Health Sciences by 689.4% in the third quarter. GAMMA Investing LLC now owns 2,763 shares of the company's stock worth $40,000 after acquiring an additional 2,413 shares during the last quarter. State of Wyoming bought a new position in shares of USANA Health Sciences in the first quarter worth about $57,000. State of Alaska Department of Revenue lifted its position in shares of USANA Health Sciences by 79.3% during the third quarter. State of Alaska Department of Revenue now owns 11,950 shares of the company's stock worth $172,000 after purchasing an additional 5,284 shares in the last quarter. Finally, DGS Capital Management LLC acquired a new position in shares of USANA Health Sciences during the first quarter worth approximately $208,000. Institutional investors and hedge funds own 54.25% of the company's stock.

USANA Health Sciences News Roundup

Here are the key news stories impacting USANA Health Sciences this week:

• Positive Sentiment: Sidoti slightly raised its Q4 2026 EPS estimate to $0.12 from $0.11, a modest offset to its broader forecast reductions. USANA analyst estimates
• Negative Sentiment: USANA’s Q3 2026 results missed expectations: the company reported a loss of $0.11 per share versus consensus earnings of $0.11, while revenue of $205.9 million fell short of the $217.4 million estimate. Sales declined 4% year over year. USANA Q3 results and outlook
• Negative Sentiment: The company lowered its FY2026 outlook, now projecting net sales approaching $900 million and adjusted EBITDA of approximately $77 million. The reduced guidance suggests weaker near-term business performance. USANA updates its outlook
• Negative Sentiment: Sidoti lowered its FY2027 EPS forecast to $1.59 from $1.77 and cut estimates for Q1, Q2, and Q3 2027, indicating less confidence in earnings growth beyond 2026. USANA analyst estimates

Wall Street Analysts Forecast Growth

Several analysts have recently commented on USNA shares. Zacks Research raised shares of USANA Health Sciences from a "strong sell" rating to a "hold" rating in a research note on Monday, October 5th. Weiss Ratings restated a "sell (d)" rating on shares of USANA Health Sciences in a research report on Monday, September 21st. Finally, Wall Street Zen cut shares of USANA Health Sciences from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Reduce".

USANA Health Sciences Stock Down 3.3%

Shares of USNA opened at $13.86 on Friday. The stock's fifty day simple moving average is $14.61 and its 200-day simple moving average is $17.99. The firm has a market capitalization of $256.05 million, a PE ratio of -12.05, a price-to-earnings-growth ratio of 2.17 and a beta of 0.66. USANA Health Sciences, Inc. has a 12-month low of $12.57 and a 12-month high of $23.59.

USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of $0.11 by ($0.22). USANA Health Sciences had a positive return on equity of 3.56% and a negative net margin of 2.34%. The firm had revenue of $205.89 million during the quarter, compared to analyst estimates of $217.42 million. Analysts anticipate that USANA Health Sciences, Inc. will post 0.55 EPS for the current year.

USANA Health Sciences Profile

USANA Health Sciences, Inc develops and sells nutritional supplements, healthy foods and personal-care products through a direct-selling business model. Its product portfolio includes vitamins and mineral supplements, meal-replacement and snack products, sports nutrition offerings, and skincare products marketed under the USANA and related brands.

Founded in 1992 by microbiologist and immunologist Myron W. Wentz, the company is headquartered in Salt Lake City, Utah. USANA distributes its products through a network of independent associates and preferred customers rather than primarily through traditional retail channels.

The company serves customers in markets across the Americas, Asia-Pacific and Europe, with a significant presence in countries including the United States, Canada, Australia, New Zealand, China, Hong Kong, Japan, South Korea, the Philippines, Singapore, Malaysia and Thailand.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.